13 January 2026 - The approval is based on clinically significant results from UCB's two pivotal Phase 3 trials demonstrating significant clinical improvements in patients' disease activity globally compared to placebo at Week 16 with Hurley Stage II/III hidradenitis suppurativa and inadequate response to antibiotics when treated with Bimzelx (bimekizumab injection).

UCB Canada is pleased to announce Health Canada has granted a Notice of Compliance for Bimzelx (bimekizumab injection) indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa with an inadequate response to conventional systemic therapy.

Read UCB press release